Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
117.65
+6.09 (5.46%)
Nov 21, 2024, 2:06 PM EST - Market open
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for LGND stock have an average target of 144.83, with a low estimate of 135 and a high estimate of 157. The average target predicts an increase of 23.10% from the current stock price of 117.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LGND stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $130 → $140 | Buy | Maintains | $130 → $140 | +19.00% | Nov 12, 2024 |
| Benchmark | Benchmark | Strong Buy Maintains $110 → $135 | Strong Buy | Maintains | $110 → $135 | +14.75% | Nov 8, 2024 |
| Barclays | Barclays | Buy Maintains $125 → $150 | Buy | Maintains | $125 → $150 | +27.50% | Nov 8, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $135 → $147 | Buy | Maintains | $135 → $147 | +24.95% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $157 | Strong Buy | Reiterates | $157 | +33.45% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
161.76M
from 131.31M
Increased by 23.19%
Revenue Next Year
186.15M
from 161.76M
Increased by 15.08%
EPS This Year
5.50
from 2.94
Increased by 87.28%
EPS Next Year
6.10
from 5.50
Increased by 11.02%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 182.9M | 204.8M | 246.8M | ||
| Avg | 161.8M | 186.2M | 219.9M | ||
| Low | 146.5M | 165.4M | 199.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 39.3% | 26.6% | 32.6% | ||
| Avg | 23.2% | 15.1% | 18.1% | ||
| Low | 11.6% | 2.2% | 7.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 5.78 | 6.89 | 8.58 |
| Avg | 5.50 | 6.10 | 7.51 |
| Low | 5.15 | 4.67 | 6.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 97.0% | 25.3% | 40.5% |
| Avg | 87.3% | 11.0% | 23.0% |
| Low | 75.2% | -15.0% | -0.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.